H Lundbeck A/S v Sandoz Pty Ltd

Link copied
Case Copied 56 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

H Lundbeck A/S v Sandoz Pty Ltd [2019] APO 18

Patent:623144

Title: (+)-Enantiomer of citalopram and process for the preparation thereof

Applicant for licence:             Sandoz Pty Ltd

Patentee and Opponent:         H Lundbeck A/S

Hearing Officer:  Dr S.D. Barker – Deputy Commissioner of Patents

Decision Date:  11 April 2019

Hearing Date:  19 November 2018 and 18 March 2019 in Canberra

Catchwords:  PATENTS – section 223(9) and regulation 22.21 – application for licence to exploit – opposition to the application – relevant considerations – exploitation found – definite steps to exploit not found – patent ceased – application for extension of term was not filed in time – exploitation was because of the failure to file the for extension of term in time – balance of discretionary considerations – grant of licence – costs

Representation:  Counsel for the patentee:  A. Bannon SC and L. Merrick

Solicitor for the opponent:  Corrs Chambers Westgarth

Counsel for the licence applicant:  J. Hennessy SC and P. Arcus

Solicitor for the applicant:  Clayton Utz

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent:623144

Title:(+)-Enantiomer of citalopram and process for the preparation thereof

Patentee:  H Lundbeck A/S

Date of Decision:                   11 April 2019

DECISION

I grant to Sandoz Pty Ltd a licence to exploit the invention claimed in patent number 623144.  The licence is granted subject to the following terms.

1.The licence commences on 14 June 2009 and continues until the expiration of the term of the patent on 9 December 2012.

2.The licence is personal to Sandoz Pty Ltd in the sense that:

a)   it belongs to that company;

b)   it may be transferred with that company if that company changes hands by acquisition or merger, but it cannot be assigned or transferred; and

c)   it cannot be sublicenced.

I direct that details of the licence be entered in the Register of Patents.

I award costs in accordance with Schedule 8 of the Regulations against H Lundbeck A/S.

Pursuant to section 224(2) and regulation 22.26(3) I give notice to the parties that, subject to the Administrative Appeals Tribunal Act 1975, application may be made to the Administrative Appeals Tribunal for review of this decision by or on behalf of the person or persons whose interests are affected by the decision.

REASONS FOR DECISION

  1. Patent application number 36295/89 was filed on 13 June 1989 under the provisions of the Patents Act 1952.[1]  A patent was granted on 31 August 1992 as patent number 623144 (the patent).  The patentee is H Lundbeck A/S (Lundbeck). Pursuant to section 234(2) of the Patents Act 1990 (the Act), it is the 1990 Act that applies to the patent, including the provisions of Chapter 6.[2] The term of the patent has been extended under section 76 of the Act until 9 December 2012.

    [1] As far as I can determine, this is the only patent filed under the provisions of the Patents Act 1952 that is still subject to proceedings before the Commissioner.

    [2] Part…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read H Lundbeck A/S v Sandoz Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2019] APO 18
Decision Date

CaseChat Overview and Summary

H Lundbeck A/S (Lundbeck) holds patent number 623144 for the (+)-enantiomer of citalopram and a process for its preparation. Sandoz Pty Ltd (Sandoz) applied for a licence to exploit the invention under section 223(9) of the Patents Act 1990 (Act). Lundbeck opposed the application. The Commissioner found that Sandoz exploited the invention by importation and sale of products containing the (+)-enantiomer of citalopram, but not by taking definite steps to exploit. The exploitation was because of the failure to file an application for extension of term of the patent in time and the ceasing of the patent. The Commissioner found that a licence should be granted to Sandoz. Lundbeck appealed to the Federal Court. The Federal Court found that Sandoz had infringed the patent and that the extension of term based on Lexapro was invalid. The appeal to the Full Court of the Federal Court is ongoing. The Commissioner found that there was a discretion to grant a licence, and that a licence should be granted to Sandoz. The Commissioner granted a licence to Sandoz and ordered Lundbeck to pay costs.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.